Example: Heart Attack

Search clinical trials for: Cisplatin

Total 4353 results

NCT06055153

Not yet recruiting

DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC

HER-2 Protein Overexpression | Esophageal Squamous Carcinoma
NCT06050252

Not yet recruiting

Durvalumab With Gemcitabine and Cisplatin for the Treatment of High Risk Resectable Liver Cancer Before Surgery

Intrahepatic Cholangiocarcinoma
NCT06048133

Not yet recruiting

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers

Cholangiocarcinoma | Bile Duct Cancer | Biliary Tract Carcinoma
NCT06040970

Not yet recruiting

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

Ovarian Cancer | Malignant Neoplasm of Uterus
NCT06041035

Not yet recruiting

A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors

Solid Tumor
NCT06041724

Not yet recruiting

Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma

Advanced Mucosal Melanoma
NCT06039631

Recruiting

Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer

Hypopharyngeal Cancer | Larynx Cancer
NCT06037980

Not yet recruiting

CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence (PURITY)

Cholangiocarcinoma | Biliary Tract Cancer
NCT06037655

Not yet recruiting

Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC (Modified)

Biliary Tract Neoplasms
NCT06031597

Not yet recruiting

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Non-small Cell Lung Cancer Stage III
NCT06029270

Not yet recruiting

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Nasopharyngeal Carcinoma
NCT06026878

Recruiting

GNT Induction Treatment in Locally Advanced NPC

Nasopharyngeal Carcinoma
NCT06023875

Recruiting

Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma (NCCCNRHNSCC)

Head and Neck Squamous Cell Carcinoma | Locally Advanced Operable
NCT06022861

Not yet recruiting

A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
NCT06020885

Recruiting

Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.

Esophageal Squamous Cell Carcinoma
NCT06019130

Recruiting

Nivolumab in Children and Adults With Nasopharyngeal Carcinoma (NPC-Nivo)

Nasopharyngeal Carcinoma | Nasopharyngeal Cancer | Nasopharynx Cancer | Nasopharyngeal Neoplasms
NCT06016699

Recruiting

Immunological Function After Radiation With Either Proton or Photon Therapy (PRO-IMMUNO)

Head and Neck Cancer | Oropharynx Cancer | Larynx Cancer | HNSCC | Hypopharynx Cancer
NCT06017297

Not yet recruiting

Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma (ESR-22-21719)

Biliary Tract Cancer | Borderline Resectable Carcinoma
NCT06013943

Recruiting

Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC

Gallbladder Cancer
NCT06010303

Not yet recruiting

A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Cancer | Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma by AJCC V8 Stage
NCT06009861

Recruiting

Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)

Oropharyngeal Squamous Cell Carcinoma | Oral Squamous Cell Carcinoma
NCT06008106

Not yet recruiting

Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma

Melanoma
NCT06008093

Not yet recruiting

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients (TRITON)

Carcinoma, Non-Small-Cell Lung
NCT06006650

Recruiting

Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell

Chemotherapy | Esophageal Squamous Cell Carcinoma | PD-1 Inhibitor | Neoadjuvent
NCT06005324

Not yet recruiting

Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer

HPV-Negative Squamous Cell Carcinoma
NCT06001658

Not yet recruiting

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

Pancreatic Cancer
NCT05998941

Not yet recruiting

A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer

Cervical Cancer
NCT05996484

Not yet recruiting

Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

Neoadjuvant Therapy | Esophageal Carcinoma
NCT05994339

Not yet recruiting

Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer

Lung Cancer Stage III
NCT05994300

Recruiting

Moderately Hypofractionated Adaptive Radiotherapy for Cervical Cancer

Cervical Neoplasm | Radiotherapy; Adverse Effect | Adaptive Radiotherapy
NCT05993858

Not yet recruiting

Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC (PC-1)

Head and Neck Squamous Cell Carcinoma | Neoadjuvant Therapy
NCT05992597

Recruiting

ZR2 Sequential Immunochemotherapy for Newly Treated MCL

Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma
NCT05991518

Recruiting

IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors

HER2 Gene Mutation
NCT05984342

Recruiting

Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
NCT05980715

Recruiting

PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-003)

Radiotherapy | HNSCC | PD-1
NCT05979961

Not yet recruiting

Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
NCT05978193

Recruiting

Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Cancer | Esophageal Squamous Cell Carcinoma | Metastatic Esophageal Squamous Cell Carcinoma
NCT05979818

Not yet recruiting

Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer (BRIO)

Non Small Cell Lung Cancer | Propranolol
NCT05978609

Recruiting

Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer

Cholangiocarcinoma Non-resectable
NCT05973773

Recruiting

A Study of Zipalertinib and Chemotherapy Compared With Chemotherapy Alone in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion. (REZILIENT3)

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
NCT05975307

Not yet recruiting

Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation (BCIRT-01)

Muscle-Invasive Bladder Carcinoma | Radiotherapy | Programmed Cell Death Protein 1 Inhibitor
NCT05967182

Not yet recruiting

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma
NCT05966194

Not yet recruiting

Efficacy Study of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers (KEVLARx)

Oral Mucositis
NCT05966233

Not yet recruiting

R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma (FIL_POLARDHAP)

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory
NCT05948462

Recruiting

Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib (NSCLC)

Lung Cancer | Non-small Cell Lung Cancer
NCT05947201

Recruiting

Neoadjuvant Treatment of Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC
NCT05946577

Not yet recruiting

Association Between Tinnitus and Hearing Loss in Locally Advanced Head and Neck Cancer Treated by Radiotherapy Alone or With Chemotherapy: a Prospective and Multicenter Study (AURACCO)

Head Cancer | Neck Cancer
NCT05945823

Recruiting

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Locally Advanced Unresectable or Metastatic Esophageal Cancer
NCT05944809

Not yet recruiting

The Effect of Prophylactic TPO Combined With BMS-IMRT to Esophageal Cancer Patients

Esophageal Cancer | Thrombocytopenia | Concurrent Chemoradiotherapy | Intensity-modulated Radiation Therapy
NCT05941741

Not yet recruiting

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Nasopharyngeal Carcinoma | Chemotherapy | Radiotherapy | Immune Checkpoint Inhibitor

Search clinical trials for: Cisplatin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations